VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Cataracts
Interventions
DRUG

Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)

One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.

DRUG

Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)

One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01515826 - VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery | Biotech Hunter | Biotech Hunter